PTX · ASX

Prescient Therapeutics Limited (ASX:PTX)

AU$0.051

 0.001 (2.0%)
ASX:Live
09/05/2025 04:10:18 PM
Hammer Bullish HALO Price Momentum HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PTX Overview

PTX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About PTX

Website

Prescient Therapeutics Limited

Telephone

61.3.9692.7222

Address

Level 4 100 Albert Road South Melbourne, Victoria (VIC) 3205

Description

Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded on May 22, 1986, and is headquartered in South Melbourne, Australia.

PTX Price Chart

Key Stats

Market Cap

AU$38.66M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.04 - 0.06

Trade Value (12mth)

AU$7,105.00

1 week

6.38%

1 month

28.21%

YTD

-1.96%

1 year

16.28%

All time high

184.85

Key Fundamentals

EPS 3 yr Growth

50.00%

EBITDA Margin

N/A

Operating Cashflow

-$7m

Free Cash Flow Return

-33.50%

ROIC

-37.30%

Interest Coverage

N/A

Quick Ratio

8.10

Other Data

Shares on Issue (Fully Dilluted)

805m

HALO Sector

Healthcare

Next Company Report Date

01-Sep-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PTX Announcements

Latest Announcements

Date Announcements

06 May 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

02 May 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

28 April 25

March 2025 Quarterly Update and Appendix 4C

×

March 2025 Quarterly Update and Appendix 4C

17 April 25

Prescient Therapeutics - Investor Briefing

×

Prescient Therapeutics - Investor Briefing

16 April 25

PTX-100 receives U.S. FDA Fast Track Designation

×

PTX-100 receives U.S. FDA Fast Track Designation

11 April 25

Initial Director's Interest Notice

×

Initial Director's Interest Notice

10 April 25

PTX appoints Melanie Farris as Non-Executive Director

×

PTX appoints Melanie Farris as Non-Executive Director

01 April 25

Final Director's Interest Notice

×

Final Director's Interest Notice

31 March 25

Prescient Therapeutics - Investor Briefing

×

Prescient Therapeutics - Investor Briefing

26 March 25

PTX Opens First Clinical site for PTX-100 Phase 2a Study

×

PTX Opens First Clinical site for PTX-100 Phase 2a Study

24 March 25

Change of Chief Medical Officer

×

Change of Chief Medical Officer

21 March 25

PTX-100 clinical data presented at leading TCL meeting

×

PTX-100 clinical data presented at leading TCL meeting

17 March 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

11 March 25

Change of Board Chair

×

Change of Board Chair

21 February 25

Appendix 4D and Half Year Financial Report

×

Appendix 4D and Half Year Financial Report

31 January 25

December 2024 Quarterly Update and Appendix 4C

×

December 2024 Quarterly Update and Appendix 4C

31 January 25

December 2024 Quarterly Update and Appendix 4C - amended

×

December 2024 Quarterly Update and Appendix 4C - amended

23 January 25

OmniCAR technical issues resolved and program to progress

×

OmniCAR technical issues resolved and program to progress

22 January 25

Notification regarding unquoted securities - PTX

×

Notification regarding unquoted securities - PTX

22 January 25

Final Director's Interest Notice

×

Final Director's Interest Notice

13 January 25

Notification of cessation of securities - PTX

×

Notification of cessation of securities - PTX

23 December 24

US FDA allows PTX-100 Ph2 trial

×

US FDA allows PTX-100 Ph2 trial

17 December 24

Appointment of Chief Executive Officer

×

Appointment of Chief Executive Officer

11 December 24

Notification regarding unquoted securities - PTX

×

Notification regarding unquoted securities - PTX

11 December 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

PTX Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -16.2 -21.5 -6.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21.2 -23.8 3.8 Lock Lock Lock
     Yield % Lock Lock Lock Lock -4.3 -10.5 -24.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.03 0.03 0.02 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 0.03 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.1 37.7 -27.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 648 728 805 Lock Lock Lock
Basic m Lock Lock Lock Lock 648 728 805 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 7 10 11 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -196.0 -48.8 65.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -7 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.8 -39.3 -10.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -7 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.8 -39.3 -10.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -9 -12 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -2 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -5 -7 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.3 -36.9 -17.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -4 -6 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -16 12 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 16 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -4 -6 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -8.7 -43.4 -19.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 12 22 15 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 18 28 20 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -12 -22 -14 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 17 26 18 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 17 26 18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.9 55.6 -30.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -29.0 -24.9 -40.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -30.5 -26.9 -45.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -38.0 -46.2 -49.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -27.5 -32.7 -37.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -23.2 -28.9 -33.5 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -1,086.3 N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.7 2.2 1.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -73.3 -84.0 -78.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 17.6 12.2 8.1 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 17.6 12.2 8.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 86.2 88.6 77.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -533.0 -305.5 -319.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -29.0 -24.9 -40.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -30.5 -26.9 -45.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -30.5 -26.9 -45.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 96,052.6 202,777.8 912,500.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -96,052.6 -202,777.8 -912,500.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PTX Shortsell

Frequently Asked Questions

The current share price of Prescient Therapeutics Limited (PTX:ASX) is AU$0.051.
The 52-week high share price for Prescient Therapeutics Limited (PTX:ASX) is AU$0.06.
The 52-week low share price for Prescient Therapeutics Limited (PTX:ASX)? is AU$0.04.
Prescient Therapeutics Limited (PTX:ASX) does not pay a dividend.
Prescient Therapeutics Limited (PTX:ASX) does not pay a dividend.
Prescient Therapeutics Limited (PTX:ASX) has a franking level of 0.0%.
Prescient Therapeutics Limited (PTX:ASX) is classified in the Healthcare.
The current P/E ratio for Prescient Therapeutics Limited (PTX:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.